Stay updated on Johnson & Johnson Press Releases

Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Johnson & Johnson Press Releases page

  1. Check
    24 days ago
    Change Detected
    Summary
    The page has been updated to include information about Johnson & Johnson's participation in the upcoming TD Cowen Healthcare Conference, while a previous statement regarding VARIPULSE™ has been removed.
    Difference
    12%
    Check dated 2025-02-10T16:50:50.000Z thumbnail image
  2. Check
    32 days ago
    Change Detected
    Summary
    The website has updated to show 2,098 results and added a positive opinion from the CHMP recommending subcutaneous RYBREVANT® for advanced EGFR-mutated non-small cell lung cancer, highlighting its advantages over intravenous administration.
    Difference
    16%
    Check dated 2025-02-03T11:50:30.000Z thumbnail image
  3. Check
    39 days ago
    Change Detected
    Summary
    Recent updates include the publication of pivotal Phase 3 study findings for nipocalimab in generalized myasthenia gravis, the FDA approval of SPRAVATO® as a monotherapy for treatment-resistant depression, and the European Commission's approval of LAZCLUZE® in combination with RYBREVANT® for EGFR-mutated lung cancer, highlighting significant advancements in treatment options.
    Difference
    100%
    Check dated 2025-01-27T06:40:54.000Z thumbnail image
  4. Check
    46 days ago
    Change Detected
    Summary
    Johnson & Johnson has initiated a New Drug Application for TAR-200, a groundbreaking treatment for bladder cancer, and strengthened its neuroscience portfolio by acquiring Intra-Cellular Therapies, which includes the promising drug CAPLYTA® for depression and schizophrenia.
    Difference
    44%
    Check dated 2025-01-20T03:51:27.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Recent updates include the CE Mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for AFib treatment, FDA Priority Review for Nipocalimab in myasthenia gravis, and Fast Track designations for two Alzheimer’s therapies, highlighting significant advancements in medical technologies.
    Difference
    100%
    Check dated 2025-01-12T23:25:20.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The website now features 2,086 results, including a significant announcement from Johnson & Johnson regarding their quarterly dividend for Q1 2025, and the European Commission's approval of RYBREVANT® in combination with LAZCLUZE® for treating advanced non-small cell lung cancer, which showed a 30% improvement over existing therapies.
    Difference
    36%
    Check dated 2025-01-05T16:29:30.000Z thumbnail image

Stay in the know with updates to Johnson & Johnson Press Releases

Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.